- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Florham Park Today
By the People, for the People
Celularity Sells $126M in New Jersey Tax Credits for $12.2M
The biotech company will use the non-dilutive capital to support its regenerative medicine programs.
Published on Feb. 10, 2026
Got story updates? Submit your updates here. ›
Celularity Inc., a regenerative and cellular medicine company, has received $12.2 million in net cash proceeds from the sale of approximately $126.3 million of its unused New Jersey net operating losses (NOLs) and $1.9 million of unused New Jersey research and development (R&D) tax credits. The sale was facilitated through New Jersey's Technology Business Tax Certificate Transfer Program, which enables qualified state-based tech and life science companies to sell their NOLs and R&D tax credits for cash.
Why it matters
The funds provide Celularity with non-dilutive, tax-free capital that strengthens the company's balance sheet and enhances liquidity. This supports Celularity's efforts to commercialize its GMP-level stem cell and other cell therapies and regenerative medicine programs targeting longevity and human performance preservation.
The details
Celularity sold the NOLs and R&D tax credits through New Jersey's Technology Business Tax Certificate Transfer Program, which is operated by the New Jersey Economic Development Authority (NJEDA). The program enables qualified state-based tech and life science companies to monetize their unused tax assets.
- Celularity received the $12.2 million in net cash proceeds on February 10, 2026.
The players
Celularity Inc.
A regenerative and aging-related cellular medicine company developing advanced biomaterial products and cell therapies derived from the postpartum placenta.
New Jersey Economic Development Authority (NJEDA)
The state's principal agency for driving economic growth, which operates the Technology Business Tax Certificate Transfer Program.
Robert J. Hariri, M.D., Ph.D.
Chairman and Chief Executive Officer of Celularity.
What they’re saying
“The funds Celularity received under this program provide non-dilutive, tax-free capital that strengthens our balance sheet and enhances liquidity as well as supports disciplined capital allocation to commercial opportunities for our GMP-level stem cell and other cell therapies and regenerative medicine programs, all targeting longevity and the preservation of human performance.”
— Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity (Celularity Press Release)
The takeaway
Celularity's ability to monetize its unused New Jersey tax assets demonstrates the value of state-level programs that support innovative life science companies. The $12.2 million in non-dilutive capital will help Celularity advance its regenerative medicine pipeline and commercialization efforts without diluting existing shareholders.
